KVUE Kenvue Stock Outlook 2026: The JNJ Overhang Is the Real Story
Kenvue (NYSE: KVUE) stock analysis — Tylenol, Listerine, Neutrogena, Band-Aid, Aveeno. FY2025 revenue $15.1B, ~3.8% dividend yield, JNJ stake selldown nearing completion. Consumer healthcare giant at a crossroads between overhang resolution and growth reacceleration.
KVUE Kenvue consumer healthcare